← Back to Search

Stem Cell Therapy

Stem Cell Therapy for Lung Disease (ADcSVF-COPD Trial)

Phase 1 & 2
Waitlist Available
Led By Glenn C. Terry, MD
Research Sponsored by Healeon Medical Inc
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Prior Diagnosis of moderate to severe COPD
GOLD II a, III, IV
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 1 year
Awards & highlights

ADcSVF-COPD Trial Summary

This trial is studying whether treating COPD with autologous (from the patient) derived cells that are expanded and concentrated is safe and can improve lung function.

Who is the study for?
This trial is for adults with moderate to severe COPD, a lung condition causing poor airflow and difficulty breathing. Candidates must not have hepatitis (except past Hepatitis A), drug/alcohol dependence, life expectancy under 3 months due to other illnesses, inherited Alpha-1 Antitrypsin Deficiency, or be pregnant/lactating. They shouldn't have used investigational drugs within the last month or be on chronic immunosuppressive/chemotherapy treatments.Check my eligibility
What is being tested?
The study tests the safety and effectiveness of using one's own adipose-derived stem/stromal cells (ADcSVF) obtained via lipoaspiration in treating COPD symptoms. It involves comparing results from this new intervention against normal saline IV treatment as a control.See study design
What are the potential side effects?
Potential side effects may include discomfort at the fat tissue extraction site from lipoaspiration, typical risks associated with intravenous procedures like bruising or infection, and unknown reactions related to ADcSVF since it's an experimental therapy.

ADcSVF-COPD Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I have been diagnosed with moderate to severe COPD.
Select...
My COPD is moderate to very severe.

ADcSVF-COPD Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~1 year
This trial's timeline: 3 weeks for screening, Varies for treatment, and 1 year for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Safety - Pulmonary Function
Secondary outcome measures
Change from Baseline Lung X-Ray
Change from Baseline Respiratory Rate
Change from Baseline SGOT Blood Testing
+4 more

ADcSVF-COPD Trial Design

3Treatment groups
Experimental Treatment
Group I: Normal Saline IV Arm 3Experimental Treatment1 Intervention
Normal Saline IV with AD-cSVF cells
Group II: Lipoaspiration Arm 1Experimental Treatment1 Intervention
Acquisition of Adipose-Derived tissue Stromal Vascular Fraction (AD-tSVF) via closed syringe harvest subdermal fat
Group III: AD-cSVF Arm 2Experimental Treatment1 Intervention
Isolation of cellular stem/stromal cells from subdermal adipose-derived cellular stromal vascular fraction (AD-cSVF)

Find a Location

Who is running the clinical trial?

Healeon Medical IncLead Sponsor
8 Previous Clinical Trials
610 Total Patients Enrolled
Terry, Glenn C., M.D.INDIV
4 Previous Clinical Trials
360 Total Patients Enrolled
Glenn C. Terry, MDPrincipal InvestigatorGlobal Alliance for Regenerative Medicine (GARM)

Media Library

AD-cSVF (Stem Cell Therapy) Clinical Trial Eligibility Overview. Trial Name: NCT02946658 — Phase 1 & 2
Lung Disease Research Study Groups: Lipoaspiration Arm 1, AD-cSVF Arm 2, Normal Saline IV Arm 3
Lung Disease Clinical Trial 2023: AD-cSVF Highlights & Side Effects. Trial Name: NCT02946658 — Phase 1 & 2
AD-cSVF (Stem Cell Therapy) 2023 Treatment Timeline for Medical Study. Trial Name: NCT02946658 — Phase 1 & 2

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is it feasible for me to partake in this research?

"To be considered for this research, participants must have a pre-existing lung disorder and fall between the ages of eighteen to eighty. Presently, there is an aim to recruit one hundred patients in total."

Answered by AI

Is there an ongoing call for participants in this experiment?

"Contrary to what is listed on clinicaltrials.gov, this trial has now closed its recruitment process as of August 1st 2022. It originally opened for enrolment on October 1st 2016 and had a total of 283 other studies recruiting participants at the same time."

Answered by AI

Does the eligibility criterion for this trial specify an age limit of 40 years or younger?

"This medical trial is open to individuals aged 18-80 years old. For those younger than 18 or older than 65, there are 26 and 270 respective studies available for them to consider participating in."

Answered by AI

Who else is applying?

How old are they?
18 - 65
What site did they apply to?
Global Alliance for Regenerative Medicine (GARM)
What portion of applicants met pre-screening criteria?
Met criteria
~15 spots leftby Aug 2025